How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
IV and Oral Iron Drugs Market
- By Route of Administration: Intravenous Iron, Oral Iron Supplements
- By Drug Type/Formulation: Iron Sucrose, Ferric Carboxymaltose, Iron Dextran, Ferrous Sulfate, Ferrous Fumarate, Ferrous Gluconate
- By Indication: Iron Deficiency Anemia, Chronic Kidney Disease-related Anemia, Pregnancy-related Anemia, Anemia due to Blood Loss, Anemia in Oncology Patients
- By End User: Hospitals, Clinics, Retail Pharmacies, Online Pharmacies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Intravenous Iron leads By Route of Administration at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 275 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.164 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.172 →
Full report · locked preview
Everything inside the IV and Oral Iron Drugs Market report
A complete, evidence-based study - 11 chapters and 115 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Route of Administration 2
Drug Type/Formulation 6
Indication 5
End User 4
Companies profiled
Pfizer Inc.
Vifor Pharma Group
AMAG Pharmaceuticals Inc.
Fresenius Kabi
Baxter International Inc.
Sanofi S.A.
AbbVie Inc.
Mylan N.V. (now part of Viatris)
Dr. Reddy's Laboratories Ltd.
Luitpold Pharmaceuticals Inc.
Sandoz International GmbH (a Novartis division)
Glenmark Pharmaceuticals Ltd.
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Vifor Pharma Group
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →AMAG Pharmaceuticals Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Fresenius Kabi
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Baxter International Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →AbbVie Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Mylan N.V. (now part of Viatris)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Dr. Reddy's Laboratories Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Luitpold Pharmaceuticals Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Sandoz International GmbH (a Novartis division)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Glenmark Pharmaceuticals Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Zhejiang Medicine Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Jiangsu Hengrui Medicine Co. Ltd.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,310M by 2033 · 5.1% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Intravenous Iron80.3
- Oral Iron Supplements19.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,624M → $2,444M · 5.2%
Europe$1,132M → $1,640M · 4.7%
Asia Pacific$1,033M → $1,428M · 4.1%
Latin America$639.7M → $1,070M · 6.6%
Middle East and Africa$492.1M → $762.4M · 5.6%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.022026
5.042027
5.042028
5.072029
5.072030
5.072031
5.102032
5.102033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Pfizer Inc.21.6
- Vifor Pharma Group24.4
- AMAG Pharmaceuticals Inc.8.8
- Fresenius Kabi4.2
- Baxter International Inc.7.9
- Sanofi S.A.5.0
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Route of Administration26.3%
Drug Type/Formulation14.8%
Indication27.5%
End User31.4%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.3
- Europe22.3
- Asia Pacific19.4
- Latin America14.6
- Middle East and Africa10.4
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Pfizer Inc. | 87 | 84 | 79 | 76 | 82 | 80 | 81 |
| Vifor Pharma Group | 68 | 78 | 80 | 91 | 84 | 71 | 79 |
| AMAG Pharmaceuticals Inc. | 70 | 88 | 84 | 74 | 72 | 77 | 78 |
| Fresenius Kabi | 65 | 63 | 66 | 76 | 79 | 58 | 68 |
| Baxter International Inc. | 71 | 69 | 75 | 55 | 64 | 72 | 68 |
| Sanofi S.A. | 55 | 57 | 58 | 56 | 50 | 47 | 54 |
| AbbVie Inc. | 62 | 41 | 65 | 63 | 52 | 57 | 57 |
| Mylan N.V. (now part of Viatris) | 36 | 51 | 48 | 54 | 56 | 46 | 49 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Pfizer Inc.
- Vifor Pharma Group
- AMAG Pharmaceuticals Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Pfizer Inc. | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Vifor Pharma Group | ✓ | ✓ | ◐ | ◐ | ✓ | ✓ |
| AMAG Pharmaceuticals Inc. | − | ◐ | ◐ | ◐ | ✓ | ✓ |
| Fresenius Kabi | ◐ | ◐ | ◐ | ✓ | ✓ | − |
| Baxter International Inc. | ◐ | ◐ | ◐ | − | ◐ | ◐ |
| Sanofi S.A. | ◐ | ◐ | − | − | ◐ | − |
| AbbVie Inc. | − | − | ◐ | ◐ | ◐ | − |
| Mylan N.V. (now part of Viatris) | − | ◐ | ◐ | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Pfizer Inc.81
2Vifor Pharma Group79
3AMAG Pharmaceuticals Inc.78
4Fresenius Kabi68
5Baxter International Inc.68
6AbbVie Inc.57
7Sanofi S.A.54
8Mylan N.V. (now part of Viatris)49
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Pfizer Inc.Vifor Pharma GroupAMAG Pharmaceuticals Inc.
Challenger2
Strong scale, closing on the leaders.
Fresenius KabiBaxter International Inc.
Contender1
Focused players with pockets of strength.
AbbVie Inc.
Niche2
Specialists in a single segment or region.
Sanofi S.A.Mylan N.V. (now part of Viatris)
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Route of Administration in North America, then scale across IV and Oral Iron Drugs Market — a $330M beachhead inside a $4.37B market.
Beachhead (SOM)$330Mobtainable near-term
Serviceable (SAM)$1.78Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Intravenous Iron
Best fit — highest urgency & budget in Route of Administration.
Economic buyer77 fit
Oral Iron Supplements
Strong fit — clear ROI and a fast path to value.
End user64 fit
Enterprise buyers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Route of Administration in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Drug Type/Formulation & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Indication
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel28%
Digital / self-serve20%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Route of Administration leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win IV and Oral Iron Drugs Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified22%
Evaluation14%
Closed-won8%
$14.3KCAC
$70KLTV
4.9:1LTV : CAC
< 3 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
IV and Oral Iron Drugs Market is a high-growth opportunity — $4.36B by 2033, compounding at 10.7%.
TAM · 2025$1.93Btoday
TAM · 2033$4.36Bforecast
CAGR10.7%2027–2033
Cumulative$27.0Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$4.36BTotal addressable market
SAM$1.82BServiceable available market
SOM$346MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.7% CAGR
Demand compounds through 2033, outpacing GDP across Route of Administration.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Route of Administration moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$4.36BLarge & growingTAM by 2033 at 10.7% CAGR
$1.82BServiceable nowreachable with today’s model
$346MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$3.40BBear7.0% CAGR
$4.36BBase10.7% CAGR
$5.58BBull14.2% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Drug Type/Formulation optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
IV and Oral Iron Drugs Market — a $4.53B market by 2033. Plan: grow share from 10.2% to 16.9%.
Market size · 2033$4.53Btotal addressable
Market CAGR6.2%2027–2033
Target share16.9%from 10.2% today
Revenue ambition$765Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.2% | 16.9% | On track |
| Revenue | $490M | $765M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 32.1% | 45.3% | At risk |
| Customer retention | 90.5% | 95.3% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Route of Administration
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Drug Type/Formulation capability
A defensible second engine — invest in Drug Type/Formulation to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Route of Administration share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Drug Type/Formulation
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $96M capacity & capability investment
- Greenlight bolt-on M&A in Drug Type/Formulation
- Authorise North America expansion plan
- Fund R&D program for Route of Administration leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAhead
- Competitive share lossAhead
- Input-cost & supply riskAt risk
- Regulatory / policy changeBehind
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the IV and Oral Iron Drugs Market conversation — a $1.11B market you can size, segment and defend in minutes.
Market size · 2033$1.11Btotal opportunity
Growth6.6%CAGR to 2033
Addressable buyers1,495+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Route of Administration
Goal Grow share in Route of Administration
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 3 mopayback period
$67K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Pfizer Inc.Vifor Pharma GroupAMAG Pharmaceuticals Inc.Fresenius KabiBaxter International Inc.Sanofi S.A.AbbVie Inc.Mylan N.V. (now part of Viatris)+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your IV and Oral Iron Drugs Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
IV and Oral Iron Drugs Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Legalize Marijuana Market
Market size, share, segmentation and regional forecast.
$3.9B market · 2025 base year
View reportAntispasmodic and Anticholinergic H2 Blocking Agents Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportAnti Adrenergic Agent Market
Market size, share, segmentation and regional forecast.
$5.4B market · 2025 base year
View reportPet Eye Care Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportTurmeric Supplement Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportProbiotic-based Dietary Supplements Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportHyperosmotic Laxatives Market
Market size, share, segmentation and regional forecast.
$2.0B market · 2025 base year
View reportCough Suppressants Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportCough Syrup Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportPoliomycetes Vaccine in Dragee Candy (Monkey Liver Cell) Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportFosfomycin Calcium Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportOral Polio Vaccines (OPV) Market
Market size, share, segmentation and regional forecast.
$2.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.